Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetic Peripheral Neuropathy, Diabetes, Postherpetic Neuralgia, Diabetic Peripheral Neuropathic Pain
- Main trialPhase 2
- “Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.”In the company’s words, NCT04455633 on ClinicalTrials.gov
Other drugs for Diabetic Peripheral Neuropathy
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 23 May 2022 | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain | |
| Phase 2Completed | 18 Nov 2022 | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia | |
| Phase 2Completed | 14 Jan 2025 | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026